A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma
Randomized trial evaluates efficacy of Mosun-Pola versus R-Pola in relapsed large B-cell lymphoma, indicating a significant therapeutic advantage.
Key Points
The study aims to compare the efficacy of subcutaneous mosunetuzumab plus polatuzumab vedotin versus rituximab plus polatuzumab vedotin in patients with relapsed or refractory large B-cell lymphoma.
Phase II randomized trial with patients having relapsed/refractory LBCL and ≥ 1 prior therapy.
Patients received either Mosun-Pola or R-Pola with specified dosing schedules.
Primary endpoint was best objective response rate.
Best objective response rate was 77.5% for Mosun-Pola versus 50.0% for R-Pola (p<0.001).
Median progression-free survival was significantly longer at 25.4 months for Mosun-Pola compared to 6.4 months for R-Pola (HR 0.47).
Cytokine release syndrome occurred in 12.5% of Mosun-Pola patients, all Grade 1/2.